ID   KYM-1
AC   CVCL_3007
SY   Kym-1; KYM1
DR   CLO; CLO_0037073
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471640
DR   BioSample; SAMN10988099
DR   cancercelllines; CVCL_3007
DR   Cell_Model_Passport; SIDM00552
DR   Cosmic; 801759
DR   Cosmic; 1995475
DR   Cosmic; 2144781
DR   Cosmic-CLP; 1240166
DR   DepMap; ACH-000607
DR   EGA; EGAS00001000978
DR   GDSC; 1240166
DR   GEO; GSM827283
DR   GEO; GSM887245
DR   GEO; GSM888320
DR   GEO; GSM1670015
DR   IARC_TP53; 30110
DR   JCRB; JCRB0627
DR   LiGeA; CCLE_614
DR   LINCS_LDP; LCL-1412
DR   PharmacoDB; KYM1_799_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_3007
DR   Wikidata; Q54900787
RX   CelloPub=CLPUB00569;
RX   PubMed=1960402;
RX   PubMed=3830265;
RX   PubMed=9290701;
RX   PubMed=11921280;
RX   PubMed=17471488;
RX   PubMed=18082704;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=23665679;
RX   PubMed=23828214;
RX   PubMed=24418192;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=32758582;
RX   PubMed=35839778;
CC   Problematic cell line: Possibly misclassified. It is not certain that this cell line originate from a alveolar rhabdomyosarcoma (ARMS). It lacks the PAXA3-FOXO1 gene fusion characteristics of ARMS. Many papers classify it as an embryonal rhabdomyosarcoma (ERMS) and we accordingly describe it as such.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: ~75 hours (Note=At 30th passage) (PubMed=3830265); ~41 hours (Note=Lot 030499), ~26 hours (Note=Lot 02142012) (JCRB=JCRB0627).
CC   HLA typing: A*11:01,26:01; B*35:01,40:02; C*03:04,03:04; DQA1*05:02,05:02; DQB1*06:01,06:01; DRB1*04:04,13:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=11921280).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=74.54%; East Asian, South=24.94%; South Asian=0.51%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Neck; UBERON=UBERON_0000974.
ST   Source(s): Cosmic-CLP=1240166; JCRB=JCRB0627
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8
ST   D16S539: 9,10
ST   D5S818: 11,14
ST   D7S820: 11
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C8971; Embryonal rhabdomyosarcoma
DI   ORDO; Orphanet_99757; Embryonal rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   9M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 38
//
RX   CelloPub=CLPUB00569;
RA   Dickman P.S., Tsokos M.G., Triche T.J.;
RT   "Biology of rhabdomyosarcoma: cell culture, xenografts, and animal
RT   models.";
RL   (In book chapter) Rhabdomyosarcoma and related tumors in children and adolescents; Maurer H.M., Ruymann F.B., Pochedly C.E. (eds.); pp.49-88; CRC Press; Boca Raton; USA (1991).
//
RX   PubMed=1960402; DOI=10.1016/0022-1759(91)90239-C;
RA   Meager A.;
RT   "A cytotoxicity assay for tumour necrosis factor using a human
RT   rhabdomyosarcoma cell line.";
RL   J. Immunol. Methods 144:141-143(1991).
//
RX   PubMed=3830265;
RA   Sekiguchi M., Shiroko Y., Suzuki T., Imada M., Miyahara M., Fujii G.;
RT   "Characterization of a human rhabdomyosarcoma cell strain in tissue
RT   culture.";
RL   Biomed. Pharmacother. 39:372-380(1985).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=11921280; DOI=10.1002/gcc.10052;
RA   Uno K., Takita J., Yokomori K., Tanaka Y., Ohta S., Shimada H.,
RA   Gilles F.H., Sugita K., Abe S., Sako M., Hashizume K., Hayashi Y.;
RT   "Aberrations of the hSNF5/INI1 gene are restricted to malignant
RT   rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric
RT   solid tumors.";
RL   Genes Chromosomes Cancer 34:33-41(2002).
//
RX   PubMed=17471488; DOI=10.1002/path.2170;
RA   Lae M., Ahn E.H., Mercado-Celis G.E., Chuai S., Edgar M., Pawel B.R.,
RA   Olshen A.B., Barr F.G., Ladanyi M.;
RT   "Global gene expression profiling of PAX-FKHR fusion-positive alveolar
RT   and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.";
RL   J. Pathol. 212:143-151(2007).
//
RX   PubMed=18082704; DOI=10.1016/j.jpedsurg.2007.08.026;
RA   Komuro H., Saihara R., Shinya M., Takita J., Kaneko S., Kaneko M.,
RA   Hayashi Y.;
RT   "Identification of side population cells (stem-like cell population)
RT   in pediatric solid tumor cell lines.";
RL   J. Pediatr. Surg. 42:2040-2045(2007).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23665679; DOI=10.1038/onc.2013.129;
RA   Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.;
RT   "Proof-of-concept rare cancers in drug development: the case for
RT   rhabdomyosarcoma.";
RL   Oncogene 33:1877-1889(2014).
//
RX   PubMed=23828214; DOI=10.3892/or.2013.2588;
RA   Yamamoto Y., Fukuda K., Fuchimoto Y., Matsuzaki Y., Saikawa Y.,
RA   Kitagawa Y., Morikawa Y., Kuroda T.;
RT   "Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with
RT   EGFR amplification in vitro.";
RL   Oncol. Rep. 30:1081-1086(2013).
//
RX   PubMed=24418192; DOI=10.1111/cas.12352; PMCID=PMC4317948;
RA   Takita J., Chen Y.-Y., Kato M., Ohki K., Sato Y., Ohta S., Sugita K.,
RA   Nishimura R., Hoshino N., Seki M., Sanada M., Oka A., Hayashi Y.,
RA   Ogawa S.;
RT   "Genome-wide approach to identify second gene targets for malignant
RT   rhabdoid tumors using high-density oligonucleotide microarrays.";
RL   Cancer Sci. 105:258-264(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=32758582; DOI=10.1016/j.gene.2020.145025;
RA   Batchu S., Kellish A.S., Hakim A.A.;
RT   "Assessing alveolar rhabdomyosarcoma cell lines as tumor models by
RT   comparison of mRNA expression profiles.";
RL   Gene 760:145025.1-145025.5(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//